Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Simply Wall St.

Yesterday

Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2662489796"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662489796\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662489796?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-26 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662489796","market":"nz","top_or_hot":-1,"title":"Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story","media":"Simply Wall St.","content":"<div>\n<p>Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-26 15:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan","article_id":"2662489796","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662489796","pubTimestamp":1787729675,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first approved therapy for this rare condition in Japan.\nThe Rhythm Pharmaceuticals share price has gained 11.0% over the past month and 24.0% over the past 90 days, while the 1-year total shareholder return of 12.0% sits alongside a very large 3-year total shareholder return that is more than 4x. Recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","MEDI":"HARBOR HEALTH CARE ETF"},"translate_title":"随着日本批准提升其故事，Rhythm Pharmaceuticals (RYTM) 的估值可能被低估 15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1.5,"MEDI":0.6},"content_text":"Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first approved therapy for this rare condition in Japan. The Rhythm Pharmaceuticals share price has gained 11.0% over the past month and 24.0% over the past 90 days, while the 1-year total shareholder return of 12.0% sits alongside a very large 3-year total shareholder return that is more than 4x. Recent catalysts, including the Japan IMCIVREE approval and the appointment of a new Chief Medical Officer, appear to have maintained momentum as investors reassess growth potential and execution risk. Scan other rare disease and specialist biotech stocks showing similar momentum shifts with our hand picked 18 high quality undiscovered gems to see how Rhythm Pharmaceuticals fits into the wider opportunity set. Rhythm Pharmaceuticals now has clear traction in a rare disease niche and a share price that has moved sharply over 3 years. The crucial issue is whether the recent run already reflects that progress or still leaves potential further gains on the table. AdvertisementMost Popular Narrative: 15.4% Undervalued Rhythm Pharmaceuticals closed at $113.35, while the most followed narrative pegs fair value closer to $134. This gap sets the stage for a closer look at what is driving that view. Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. Read the complete narrative. The key narrative from peter_4mgsy focuses on expectations for rapid revenue expansion, broader obesity indications and stronger patient adoption trends. To understand this view, investors may want to examine how those elements contribute to the implied fair value and what kind of portfolio breadth supports that assessment. Result: Fair Value of $134 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Rhythm Pharmaceuticals narrative could be challenged if IMCIVREE uptake slows, or if clinical and regulatory timelines for pipeline candidates slip. Find out about the key risks to this Rhythm Pharmaceuticals narrative. Another View: Rhythm Pharmaceuticals Valuation Through Sales Multiples The user narrative leans on a fair value of $134, yet Rhythm Pharmaceuticals currently trades on a P/S ratio of 32.5x. That is well above the US Biotechs industry at 13.3x, the peer average at 9.6x, and even the fair ratio estimate of 19.5x. For investors, this gap can signal higher valuation risk if sales or sentiment disappoint. The key question is whether the growth story truly justifies paying such a premium. For a closer look at how this P/S premium stacks up against the underlying numbers, and what it could mean if the market moves closer to the fair ratio, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:RYTM P/S Ratio as at Aug 2026Next Steps If the mix of optimism and valuation questions around Rhythm Pharmaceuticals feels familiar, it may be useful to review the data directly and decide where you stand. To see what investors are currently optimistic about, have a look at the 3 key rewards. Looking for more investment ideas beyond Rhythm Pharmaceuticals? If Rhythm Pharmaceuticals has caught your attention, do not stop here. Use the Simply Wall St screener to uncover other stocks that might suit your style.  Target opportunities that combine quality and attractive pricing by scanning our hand picked 49 high quality undervalued stocks. Strengthen your focus on capital preservation by reviewing a curated 74 resilient stocks with low risk scores that aims to limit nasty surprises. Hunt for resilient businesses with robust finances using the list of solid balance sheet and fundamentals (51 results) before others catch on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}